封面
市場調查報告書
商品編碼
1124449

陣發性睡眠性血紅蛋白尿 (PNH) 治療全球市場研究報告-行業分析、規模、份額、增長、趨勢和預測 2022-2028

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2022 to 2028

出版日期: | 出版商: Value Market Research | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格

Value Market Research 深入研究了全球陣發性睡眠性血紅蛋白尿 (PNH) 治療市場,並預測未來幾年該行業將出現顯著增長。全球陣發性睡眠性血紅蛋白尿 (PNH) 治療市場報告提供了 2023 年至 2028 年的完整行業分析、市場規模、市場份額、增長趨勢和預測。該報告以詳細的市場介紹和突出報告關鍵增長數據的執行摘要開始。以下章節討論市場價值鏈、波特五力模型和市場吸引力分析。我們還將有自己的關於 COVID-19 影響分析的章節,以了解市場如何應對這一流行病。

本報告的市場動態部分詳細介紹了當前的市場驅動因素和限制因素、挑戰和風險以及即將到來的機遇。本節將引起企業戰略家和新產品開發部門的極大興趣。全球陣發性睡眠性血紅蛋白尿 (pnh) 治療市場研究細分市場並提供收入和/或銷售方面的市場規模。該數據按地區劃分,然後按國家劃分。數據是通過深入的初級訪談和來自世界各地的行業專家收集的。詳細的研究方法可以在樣本報告中找到。這些市場估計還受到最新的社會、政治和經濟變化以及當前影響陣發性夜間血紅蛋白尿 (pnh) 治療市場的市場動態的影響。

陣發性睡眠性血紅蛋白尿 (pnh) 治療市場報告的下一部分檢查了市場競爭力並介紹了一些主要的市場參與者/製造商。這些部分包含豐富的信息,可幫助您了解競爭對手的產品線、財務狀況、最近的市場發展和行業領導者。

報告的目標國家如下。

北美:美國、加拿大、墨西哥

歐洲:英國、德國、法國、意大利、俄羅斯、西班牙、其他歐洲國家

亞太地區:中國、印度、日本、韓國、澳大利亞、亞太地區的其他國家

拉丁美洲:巴西、阿根廷、秘魯、智利、拉丁美洲其他地區

中東和非洲:沙特阿拉伯、阿聯酋、以色列、南非

本報告的市場細分如下:

按產品

藥物治療

幹細胞移植

輸血

內容

第一章前言

  • 本報告的內容
    • 目的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 調查範圍
  • 調查方法
    • 市場調研流程
    • 市場調查方法

第 2 章執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章陣發性睡眠性血紅蛋白尿 (PNH) 治療 - 行業分析

  • 簡介 - 市場動態
  • 市場驅動力
  • 市場製約因素
  • 商機
  • 行業趨勢
  • 波特五力分析
  • 市場吸引力分析
    • 按處理方法分析市場吸引力
    • 按地區劃分的市場吸引力分析

第四章價值鏈分析

  • 價值鏈分析
  • 原材料分析
    • 原材料清單
    • 成分製造商列表
    • 主要原材料價格走勢
  • 潛在買家名單
  • 銷售渠道
    • 直接營銷
    • 間接營銷
    • 新興市場營銷渠道發展趨勢

第 5 章 COVID-19 爆發的影響分析

  • 分析爆發對 COVID-19 的影響
    • 對生產的直接影響
    • 供應鍊和市場中斷
    • 對公司和金融市場的財務影響
  • 分析 COVID-19 對生產、進口、出口和需求的影響
  • 在疫情爆發之前/之後銷售 COVID-19
  • 預測冠狀病毒 (COVID-19) 流行的影響
  • COVID-19:微觀和宏觀因素分析

第 6 章全球陣發性睡眠性血紅蛋白尿 (PNH) 治療市場:按治療分析

  • 按治療方法總結
  • 實際數據和預測數據
  • 按處理方法分析
  • 按地區劃分的藥物治療的實際和預測銷售額
  • 按地區劃分的干細胞移植銷售結果和預測
  • 各地區輸血銷售業績及預測

第 7 章。陣發性睡眠性血紅蛋白尿 (PNH) 治療全球市場分析:按地區劃分

  • 區域展望
  • 簡介
  • 北美銷售分析
    • 概覽、過去和未來的銷售分析
    • 北美分部銷售分析
    • 北美:按國家/地區分列的銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、過去和未來的銷售分析
    • 按細分市場劃分的歐洲銷售分析
    • 歐洲:按國家/地區劃分的銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 意大利銷售分析
    • 俄羅斯銷售分析
    • 其他歐洲銷售分析
  • 亞太地區銷售分析
    • 概覽、過去和未來的銷售分析
    • 亞太地區分部銷售分析
    • 按國家/地區劃分的亞太地區銷售分析
    • 在中國的銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳大利亞銷售分析
    • 其他亞太地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、過去和未來的銷售分析
    • 拉丁美洲分部銷售分析
    • 拉丁美洲:按國家/地區分列的銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利的銷售分析
    • 其他拉丁美洲銷售分析
  • 中東和非洲銷售分析
    • 概覽、過去和未來的銷售分析
    • 中東和非洲地區分部銷售分析
    • 按國家/地區劃分的中東和非洲銷售分析
    • 沙特阿拉伯銷售分析
    • 阿聯酋銷售分析
    • 以色列銷售分析
    • 南非的銷售分析
    • 其他中東和非洲銷售分析

第 8 章。陣發性夜間血紅蛋白尿 (Pnh) 製藥公司的競爭狀況

  • 陣發性睡眠性血紅蛋白尿(Pnh)藥物市場競爭
  • 夥伴關係、協作、協議
  • 併購
  • 新品發布
  • 其他發展

第 9 章公司簡介

  • 前 10 名公司的市場份額分析
  • 市場集中度
  • Alexion Pharmaceuticals Inc.
    • 企業概要
    • 企業收益
    • 產品介紹
    • 最近開發情況
  • Akari Therapeutics
    • 公司概要
    • 企業收益
    • 產品情報
    • 最近開發情況
  • Apellis.
    • 公司概要
    • 企業收益
    • 產品情報
    • 最近開發情況
  • Achillion.
    • 公司概要
    • 企業收益
    • 產品情報
    • 最近開發情況
  • Others
    • 公司概要
    • 企業收益
    • 產品情報
    • 最近動向

公司簡介中的財務和近期發展基於現有信息,可能不適用於私營公司。

Product Code: VMR11210464

Value Market Research deeply researched the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market to foresee a significant growth in the industry over the upcoming years. The global paroxysmal nocturnal hemoglobinuria (pnh) treatment market report provides a complete industry analysis, market size, market share, growth trends, and forecasts for 2023 to 2028. The report starts with a detailed market introduction and an executive summary that highlights the report's key growth numbers. The subsequent chapters discuss the value chain of the market, Porter's Five Forces Model, and market attractiveness analysis. An exclusive chapter on COVID-19 impact analysis has been added to understand how the market has responded to the pandemic.

The market dynamics section of the report elaborates the current market drivers, restraints along with the challenges/risks and upcoming opportunities. This section can be of high interest for any company's strategists and new product development department. The global paroxysmal nocturnal hemoglobinuria (pnh) treatment market study segments the market and provides the market size in terms of revenue and/ or sales. This data is bifurcated by region and later by countries. The data is collected through detailed primary interviews and industry experts across the world. The detailed methodology can be seen in our sample reports. These market estimates are also influenced by the latest social, political and economic changes along with the current market dynamics that are affecting this paroxysmal nocturnal hemoglobinuria (pnh) treatment market.

The next sections of the paroxysmal nocturnal hemoglobinuria (pnh) treatment market report studies the market competitiveness and profiles some key market players/manufacturers. These sections are knowledgeable for understanding the competitor's product-line, their financials, recent developments and the top market share owners in the industry.

Countries Covered in the report are as below:

North America - United States, Canada, and Mexico

Europe - United Kingdom, Germany, France, Italy, Russia, Spain & Rest of Europe

Asia-Pacific - China, India, Japan, South Korea, Australia & Rest of APAC

Latin America - Brazil, Argentina, Peru, Chile & Rest of Latin America

Middle East and Africa - Saudi Arabia, UAE, Israel, South Africa

Market Segmentation in the report is as below-

By Product

Medication

Stem Cell Transplant

Blood Transfusion

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Treatment
    • 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

  • 5.1. Impact Analysis of Covid-19 Outbreak
    • 5.1.1. Direct Impact on Production
    • 5.1.2. Supply Chain and Market Disruption
    • 5.1.3. Financial Impact on Firms and Financial Markets
  • 5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
  • 5.3. Market: Pre V/S Post COVID-19
  • 5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
  • 5.5. COVID-19: Micro and Macro Factor Analysis

6 . GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY TREATMENT

  • 6.1 Overview by Treatment
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Treatment
  • 6.4 Medication Historic and Forecast Sales by Regions
  • 6.5 Stem Cell Transplant Historic and Forecast Sales by Regions
  • 6.6 Blood Transfusion Historic and Forecast Sales by Regions

7 . GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1. Overview, Historic and Forecast Sales Analysis
    • 7.3.2. North America By Segment Sales Analysis
    • 7.3.3. North America By Country Sales Analysis
    • 7.3.4. United State Sales Analysis
    • 7.3.5. Canada Sales Analysis
    • 7.3.6. Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1. Overview, Historic and Forecast Sales Analysis
    • 7.4.2. Europe by Segment Sales Analysis
    • 7.4.3. Europe by Country Sales Analysis
    • 7.4.4. United Kingdom Sales Analysis
    • 7.4.5. France Sales Analysis
    • 7.4.6. Germany Sales Analysis
    • 7.4.7. Italy Sales Analysis
    • 7.4.8. Russia Sales Analysis
    • 7.4.9. Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1. Overview, Historic and Forecast Sales Analysis
    • 7.5.2. Asia Pacific by Segment Sales Analysis
    • 7.5.3. Asia Pacific by Country Sales Analysis
    • 7.5.4. China Sales Analysis
    • 7.5.5. India Sales Analysis
    • 7.5.6. Japan Sales Analysis
    • 7.5.7. South Korea Sales Analysis
    • 7.5.8. Australia Sales Analysis
    • 7.5.9. Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1. Overview, Historic and Forecast Sales Analysis
    • 7.6.2. Latin America by Segment Sales Analysis
    • 7.6.3. Latin America by Country Sales Analysis
    • 7.6.4. Brazil Sales Analysis
    • 7.6.5. Argentina Sales Analysis
    • 7.6.6. Peru Sales Analysis
    • 7.6.7. Chile Sales Analysis
    • 7.6.8. Rest of Latin America Sales Analysis
  • 7.7. Middle East & Africa Sales Analysis
    • 7.7.1. Overview, Historic and Forecast Sales Analysis
    • 7.7.2. Middle East & Africa by Segment Sales Analysis
    • 7.7.3. Middle East & Africa by Country Sales Analysis
    • 7.7.4. Saudi Arabia Sales Analysis
    • 7.7.5. UAE Sales Analysis
    • 7.7.6. Israel Sales Analysis
    • 7.7.7. South Africa Sales Analysis
    • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT COMPANIES

  • 8.1. Paroxysmal Nocturnal Hemoglobinuria (Pnh) Treatment Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9 . COMPANY PROFILES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT INDUSTRY

  • 9.1. Top 10 Company Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. Alexion Pharmaceuticals Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Company Revenue
    • 9.3.3. Products
    • 9.3.4. Recent Developments
  • 9.4. Akari Therapeutics
    • 9.4.1. Company Overview
    • 9.4.2. Company Revenue
    • 9.4.3. Products
    • 9.4.4. Recent Developments
  • 9.5. Apellis.
    • 9.5.1. Company Overview
    • 9.5.2. Company Revenue
    • 9.5.3. Products
    • 9.5.4. Recent Developments
  • 9.6. Achillion.
    • 9.6.1. Company Overview
    • 9.6.2. Company Revenue
    • 9.6.3. Products
    • 9.6.4. Recent Developments
  • 9.7. Others
    • 9.7.1. Company Overview
    • 9.7.2. Company Revenue
    • 9.7.3. Products
    • 9.7.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • COVID-19 Impact Analysis by Production, Import, Export and Demand
  • Pre V/S Post COVID-19
  • Estimated Impact Of The Coronavirus (Covid-19) Epidemic
  • COVID-19: Micro and Macro Factor Analysis
  • Analysis by Treatment (USD MN)
  • Medication Market Sales by Geography (USD MN)
  • Stem Cell Transplant Market Sales by Geography (USD MN)
  • Blood Transfusion Market Sales by Geography (USD MN)
  • Global Paroxysmal Nocturnal Hemoglobinuria (Pnh) Treatment Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisiton

LIST OF FIGURES

  • Research Scope of Paroxysmal Nocturnal Hemoglobinuria (Pnh) Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Paroxysmal Nocturnal Hemoglobinuria (Pnh) Treatment Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Treatment
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Treatment (USD MN)
  • Medication Market Sales by Geography (USD MN)
  • Stem Cell Transplant Market Sales by Geography (USD MN)
  • Blood Transfusion Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.